Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus DIAZEPAM INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus DIAZEPAM INTENSOL.
CENTRAX vs DIAZEPAM INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Benzodiazepine that potentiates GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and neuronal inhibition.
10-30 mg orally, 3-4 times daily.
2 to 10 mg orally 2 to 4 times daily, as needed for anxiety or muscle spasm; 10 mg orally before procedures for sedation. Maximum 40 mg/day.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Terminal elimination half-life is 20–50 hours (mean ~30 hours) in adults, with significant interindividual variability; prolonged in elderly, hepatic impairment, and neonates (up to 100 hours).
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal excretion of metabolites (primarily glucuronide conjugates) accounts for ~70% of elimination; fecal excretion accounts for ~10%; unchanged drug in urine is <1%.
Category C
Category D/X
Benzodiazepine
Benzodiazepine